PDF herunterladen
CC BY 4.0 · World J Nucl Med 2025; 24(02): 144-154
DOI: 10.1055/s-0045-1804894
Original Article

Detection Accuracy of [68Ga] PSMA PET/CT with Rising PSA in Prostate Cancer

Parul Mohan
1   Department of Nuclear Medicine, Mahajan Imaging and Labs, New Delhi, India
,
Palak Wadhwa
2   Central Research Institute, Shanghai United Imaging Healthcare, Shanghai, China
,
Harsh Mahajan
1   Department of Nuclear Medicine, Mahajan Imaging and Labs, New Delhi, India
,
Dileep Kumar
2   Central Research Institute, Shanghai United Imaging Healthcare, Shanghai, China
,
Giacomo Aringhieri
3   Department of Nuclear Medicine & PET/CT, University of Pisa, Pisa, Italy
,
Dania Cioni
3   Department of Nuclear Medicine & PET/CT, University of Pisa, Pisa, Italy
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective The objective of this study was to evaluate the clinical utility of gallium-68 [68Ga] prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) with rising prostate-specific antigen (PSA) levels in prostate cancer diagnosis.

Methods This is a retrospective, single-center, observational cross-sectional study, which is provided after ethics committee clearance, from May 2, 2022 to June 25, 2022. Study includes sample size of 50 patients with prostate adenocarcinoma with varying PSA levels and Gleason score of 6 to 9 who underwent [68Ga] PSMA PET/CT scan. The patients included in this study underwent PET/CT scan on uMI550 (United Imaging Healthcare, Shanghai, China).

Results All patients were divided into three groups based on PSA levels in ng/mL as: PSA ≤ 0.2 (8%), 0.2 < PSA ≤ 1 (10%), 1 < PSA ≤ 3 (8%), 3 < PSA ≤ 10 (18%), and PSA > 10 (56%). Among 50 scans, at least one PSMA avid lesion was visualized in 41 scans (78.9%). These scans were considered positive and included in this study, rest of the scans had insignificant PSMA uptake and were considered negative. [68Ga] PSMA PET/CT detection rates were 75.0, 20.0, 50.0, 88.90, and 89.3% in patients with PSA ≤ 0.2, 0.2 < PSA ≤ 1, 1 < PSA ≤ 3, 3 < PSA ≤ 10, and PSA > 10, respectively. In addition to prostate bed, lesions were also visualized in lymph nodes (32%), liver (2%), skeleton (28%), and thorax (6%). Considering lesions in the prostate bed a significant direct correlation was detected between maximal standardized uptake value (SUVmax) and PSA value (p = 0.03).

Discussion PSMA PET/CT has been demonstrated to be an effective method for identifying both low-grade Gleason score tumors and low PSA levels. The study provides support for the use of [68Ga] PSMA PET/CT in conjunction with PSA levels for the evaluation of prostate cancer, including local recurrence and distant metastases.

Conclusion The findings of this study indicate that PSMA PET/CT is an effective method for diagnosing prostate cancer, as it allows for the detection of high SUVmax values in pathological tissues. Furthermore, high sensitivity and detection rates are noted with PSMA PET/CT scan even in cases where PSA levels were low. Therefore, this study demonstrates that [68Ga] PSMA PET/CT is beneficial for the early detection of prostate cancer and the prediction of treatment outcomes.

Keywords

PSA - PSMA PET/CT - digital PET/CT scanner - prostate cancer - prostate-specific antigen - molecular imaging - biomarkers

Authors' Contributions

All authors contributed to the study conception, design, material preparation, data collection, and analysis. All authors read and approved the final manuscript.


Data Availability

The data sets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.


Ethical Approval

The studies involving human participants were reviewed and approved by the Institutional Review Board, Mahajan Imaging, Delhi, India. Informed consent was obtained from all individual participants included in the study (or the requirement for written consent was waived by the institutional review board). All procedures performed in studies involving human participants were in accordance with the Helsinki Declaration as revised in 2013 and its later amendments.


Declaration of Generative AI and AI-assisted Technologies in the Writing Process

During the preparation of this work the author(s) used ChatGPT to support writing the introduction section. After using this tool/service, the authors(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.




Publikationsverlauf

Artikel online veröffentlicht:
27. Februar 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Adamaki M, Zoumpourlis V. Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021; 228: 107932
    Suche in Google Scholar
  • 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424 . Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. PMID: 30207593
    Suche in Google Scholar
  • 3 Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19 (08) 1893-1907
    Suche in Google Scholar
  • 4 Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health 2019; 9 (04) 217-222
    Suche in Google Scholar
  • 5 Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J Androl 2009; 11 (01) 74-80
    Suche in Google Scholar
  • 6 Udager AM, Tomlins SA. Molecular biomarkers in the clinical management of prostate cancer. Cold Spring Harb Perspect Med 2018; 8 (11) a030601
    Suche in Google Scholar
  • 7 Tan JSH, Goh CXY, Koh YS. et al. 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med 2019; 16 (01) 157-166
    Suche in Google Scholar
  • 8 Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Front Oncol 2022; 12: 831429
    Suche in Google Scholar
  • 9 Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (01) 81-85
    Suche in Google Scholar
  • 10 Kuppermann D, Calais J, Marks LS. Imaging prostate cancer: clinical utility of prostate-specific membrane antigen. J Urol 2022; 207 (04) 769-778
    Suche in Google Scholar
  • 11 Zhou C, Tang Y, Deng Z. et al. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Res 2022; 12 (01) 10
    Suche in Google Scholar
  • 12 David MK, Leslie SW. Prostate Specific Antigen. [Updated 2022 Nov 10]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; ; January 2023
  • 13 Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol 2009; 35 (05) 521-529 , discussion 530–532
    Suche in Google Scholar
  • 14 Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34 (04) 274-292
    Suche in Google Scholar
  • 15 Ilic D, Djulbegovic M, Jung JH. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018; 362: k3519
    Suche in Google Scholar
  • 16 David MK, Leslie SW. Prostate Specific Antigen. November 10, 2022. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; ; January 2024
  • 17 United Imaging Healthcare. “HYPER DPR Deep Progressive Reconstruction,” White Paper
  • 18 Lv Y, Xi C. PET image reconstruction with deep progressive learning. Phys Med Biol 2021; 66 (10) 105016
    Suche in Google Scholar
  • 19 Wang T, Qiao W, Wang Y. et al. Can a Deep Progressive Learning Method Help to Achieve High Image Quality as Total-body PET Imaging?. Res Square 2021
    Suche in Google Scholar
  • 20 Beheshti M, Manafi-Farid R, Geinitz H. et al. Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: a prospective study of 135 patients. J Nucl Med 2020; 61 (10) 1484-1490
    Suche in Google Scholar
  • 21 Kallur KG, Ramachandra PG, Rajkumar K. et al. Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian J Nucl Med 2017; 32 (02) 110-117
    Suche in Google Scholar
  • 22 Caroli P, Sandler I, Matteucci F. et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging 2018; 45 (12) 2035-2044
    Suche in Google Scholar
  • 23 Beheshti M, Paymani Z, Brilhante J. et al. Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?. Eur J Nucl Med Mol Imaging 2018; 45 (07) 1188-1196
    Suche in Google Scholar
  • 24 Uprimny C, Kroiss AS, Decristoforo C. et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44 (06) 941-949
    Suche in Google Scholar
  • 25 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56 (05) 668-674
    Suche in Google Scholar
  • 26 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44 (08) 1258-1268
    Suche in Google Scholar
  • 27 Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 2014; 4 (06) 580-601
    Suche in Google Scholar
  • 28 Budäus L, Leyh-Bannurah SR, Salomon G. et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016; 69 (03) 393-396
    Suche in Google Scholar
  • 29 Herlemann A, Wenter V, Kretschmer A. et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016; 70 (04) 553-557
    Suche in Google Scholar
  • 30 Maurer T, Gschwend JE, Rauscher I. et al. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016; 195 (05) 1436-1443
    Suche in Google Scholar
  • 31 Thompson IM, Pauler DK, Goodman PJ. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350 (22) 2239-2246
    Suche in Google Scholar